[go: up one dir, main page]

WO2002000169A3 - Production of vaccines using transgenic plants - Google Patents

Production of vaccines using transgenic plants Download PDF

Info

Publication number
WO2002000169A3
WO2002000169A3 PCT/US2001/020272 US0120272W WO0200169A3 WO 2002000169 A3 WO2002000169 A3 WO 2002000169A3 US 0120272 W US0120272 W US 0120272W WO 0200169 A3 WO0200169 A3 WO 0200169A3
Authority
WO
WIPO (PCT)
Prior art keywords
bymv
ndv
plants
transgenic
pvy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/020272
Other languages
French (fr)
Other versions
WO2002000169A2 (en
Inventor
Rosemarie Hammond
Yan Zhao
John Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Agriculture USDA
Original Assignee
US Department of Agriculture USDA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Agriculture USDA filed Critical US Department of Agriculture USDA
Priority to CA002414396A priority Critical patent/CA2414396A1/en
Priority to AU2001270164A priority patent/AU2001270164A1/en
Publication of WO2002000169A2 publication Critical patent/WO2002000169A2/en
Publication of WO2002000169A3 publication Critical patent/WO2002000169A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Plants infected with potato virus Y (PVY) were inoculated with infectious PVX RNA encoding PVX coat protein (CP) and modified chimeric NDV/BYMV CP. Antigen-coated plate indirect ELISA and immunoelectron microscopy of virus purified from infected plants showed that progeny virions contained from <1% to as much as 25% chimeric CP. The method can be used to produce and purify large amounts of NDV vaccine. Transencapsidated PVY virions expressing NDV were purified and used to induce anti-NDV antibodies in mice. Further, transgenic tobacco plants expressing HIV/BYMV CP were inoculated with BYMV. Progeny virions from transgenic plants contained transgenic HIV/BYMV CP.
PCT/US2001/020272 2000-06-26 2001-06-26 Production of vaccines using transgenic plants Ceased WO2002000169A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002414396A CA2414396A1 (en) 2000-06-26 2001-06-26 Production of vaccines using transgenic plants
AU2001270164A AU2001270164A1 (en) 2000-06-26 2001-06-26 Production of vaccines using transgenic plants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60399700A 2000-06-26 2000-06-26
US09/603,997 2000-06-26

Publications (2)

Publication Number Publication Date
WO2002000169A2 WO2002000169A2 (en) 2002-01-03
WO2002000169A3 true WO2002000169A3 (en) 2002-07-18

Family

ID=24417757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020272 Ceased WO2002000169A2 (en) 2000-06-26 2001-06-26 Production of vaccines using transgenic plants

Country Status (3)

Country Link
AU (1) AU2001270164A1 (en)
CA (1) CA2414396A1 (en)
WO (1) WO2002000169A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000169A2 (en) * 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2434000C (en) 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle
BRPI0410340A (en) 2003-05-05 2006-05-30 Dow Agrosciences Llc vectors and cells for preparing transgenic plant-derived immunoprotective compositions
EP1732615A4 (en) * 2004-03-25 2009-09-16 Kentucky Bioproc Llc PREPARATION OF PEPTIDES IN PLANTS AS VIRUS SHELL PROTEIN FUSION
WO2005118806A2 (en) 2004-05-28 2005-12-15 Ambion, Inc. METHODS AND COMPOSITIONS INVOLVING MicroRNA
US20050287539A1 (en) * 2004-06-29 2005-12-29 Emmanuel Labourier Methods and compositions for preparing capped RNA
US20100047264A1 (en) 2006-11-15 2010-02-25 Folia Biotech Inc. Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof
WO2009036332A1 (en) 2007-09-14 2009-03-19 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
RU2370280C2 (en) * 2007-10-08 2009-10-20 Институт физико-химической биологии им. А.Н.Белозерского METHOD OF HER2/neu ONCOGENE ANTIBODY SUPERPRODUCTION IN PLANT
WO2009137807A2 (en) 2008-05-08 2009-11-12 Asuragen, Inc. Compositions and methods related to mirna modulation of neovascularization or angiogenesis
ES2380289T3 (en) 2009-11-30 2012-05-10 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and application in the medical treatment of cancer
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
CN108315493A (en) * 2018-04-23 2018-07-24 上海市农业科学院 A kind of LAMP primer group and detection method for detecting barley yellow mosaic virus
CN109486992B (en) * 2018-12-11 2021-08-20 贵州省烟草科学研究院 Specific co-dominant molecular markers and application of large deletion mutations in tobacco eIF4E-1 locus

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970168A (en) * 1989-01-27 1990-11-13 Monsanto Company Virus-resistant plants
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
WO1991015587A1 (en) * 1990-04-06 1991-10-17 Commonwealth Scientific And Industrial Research Organisation Self-polymerising expression system based on modified potyvirus coat proteins
WO1998056933A1 (en) * 1997-06-12 1998-12-17 John Innes Centre Polypeptide presentation system
US5874087A (en) * 1991-04-19 1999-02-23 Axis Genetics Plc Modified plant viruses as vectors
US5879925A (en) * 1994-08-15 1999-03-09 Connaught Laboratories Limited Genetically engineered human immunodeficiency virus-like particles with modified chimeric envelope glycoproteins containing influenza virus transmembrane spanning domains
US5998699A (en) * 1988-08-19 1999-12-07 Seminis Vegetable Seeds, Inc. Potyvirus coat protein genes and plants transformed therewith
US6232099B1 (en) * 1994-10-18 2001-05-15 Scottish Crop Research Institute Method of producing a chimeric protein
WO2002000169A2 (en) * 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041385A (en) * 1986-11-01 1991-08-20 Oxford Gene Systems Limited Vector expressing fusion proteins and particles
US5998699A (en) * 1988-08-19 1999-12-07 Seminis Vegetable Seeds, Inc. Potyvirus coat protein genes and plants transformed therewith
US4970168A (en) * 1989-01-27 1990-11-13 Monsanto Company Virus-resistant plants
WO1991015587A1 (en) * 1990-04-06 1991-10-17 Commonwealth Scientific And Industrial Research Organisation Self-polymerising expression system based on modified potyvirus coat proteins
US5874087A (en) * 1991-04-19 1999-02-23 Axis Genetics Plc Modified plant viruses as vectors
US5879925A (en) * 1994-08-15 1999-03-09 Connaught Laboratories Limited Genetically engineered human immunodeficiency virus-like particles with modified chimeric envelope glycoproteins containing influenza virus transmembrane spanning domains
US6232099B1 (en) * 1994-10-18 2001-05-15 Scottish Crop Research Institute Method of producing a chimeric protein
WO1998056933A1 (en) * 1997-06-12 1998-12-17 John Innes Centre Polypeptide presentation system
WO2002000169A2 (en) * 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946177B2 (en) 2004-11-12 2015-02-03 Mima Therapeutics, Inc Methods and compositions involving miRNA and miRNA inhibitor molecules

Also Published As

Publication number Publication date
WO2002000169A2 (en) 2002-01-03
CA2414396A1 (en) 2002-01-03
AU2001270164A1 (en) 2002-01-08

Similar Documents

Publication Publication Date Title
WO2002000169A3 (en) Production of vaccines using transgenic plants
WO2002000885A3 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2005055957A3 (en) Influenza immunogen and vaccine
DE69842165D1 (en) PREPARATION OF ATTENUATED PARAIN FLUENZA VIRUS VACCINES FROM CLONED NUCLEOTIDE SEQUENCES
NZ587108A (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
WO2003092592A3 (en) Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3&#39;-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
Hadj Hassine et al. Virus‐like particles as powerful vaccination strategy against human viruses
BR0113307A (en) Recombinant hepatitis B virus chimeric protein molecule, immunogenic particle, vaccine or inoculum, nucleic acid, recombinant nucleic acid molecule, host cell and method of inducing an immune response in an inoculated host animal
WO2002024876A3 (en) Live influenza vaccine and method of manufacture
WO2004004761A3 (en) Adjuvant viral particle
EA200300129A1 (en) CLEANING HEPATITIS B VIRUS ANTIGENS (HBV) FOR USE IN VACCINES
WO2001003744A3 (en) Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of the c, d or v genes
JP2009501001A5 (en)
WO2006136448A3 (en) Attenuated sars and use as a vaccine
EA200701695A1 (en) RNA VIRUSES WITH DECOMPOSED REPLICATION ABILITY AS VACCINES
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
WO2003049766A8 (en) Method of purifying hepatitis a virus particles and vaccine preparation
ATE427119T1 (en) RECOMBINANT RABIES VACCINE AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO1995003399A3 (en) Production method for preparation of disabled viruses
WO2000012677A3 (en) Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
ATE508185T1 (en) VIROSOME PARTICLES WITH ANTIGENS FROM INFLUENZA VIRUS AND HEPATITIS B VIRUS
WO2004050691A3 (en) A method for the production of hiv-1 gag virus-like particles
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells
WO2006078272A3 (en) Rhabdoviral n-fusion proteins as carrier for foreign antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2414396

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001270164

Country of ref document: AU

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP